Immuno-effect of Tα1 for Stage I NSCLC

To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT06598839
Phase
NA
Sponsor
Yousheng Mao
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Thymosin Alpha1
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Pathologically confirmed stage I (per AJCC 8th edition) invasive NSCLC
  • Resectable tumor
  • undergoing lobectomy and systemic lymph node dessection
  • Without a previous history of malignant tumors or other concurrent malignancies

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →